| Stereochemistry | ABSOLUTE |
| Molecular Formula | 5C8H11N3O3S.CH4O |
| Molecular Weight | 1178.323 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO.NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2.NC3=NC(=O)N(C=C3)[C@@H]4CS[C@H](CO)O4.NC5=NC(=O)N(C=C5)[C@@H]6CS[C@H](CO)O6.NC7=NC(=O)N(C=C7)[C@@H]8CS[C@H](CO)O8.NC9=NC(=O)N(C=C9)[C@@H]%10CS[C@H](CO)O%10
InChI
InChIKey=WSZXHYMIYANYOU-WSXGJQPVSA-N
InChI=1S/5C8H11N3O3S.CH4O/c5*9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6;1-2/h5*1-2,6-7,12H,3-4H2,(H2,9,10,13);2H,1H3/t5*6-,7+;/m00000./s1
| Molecular Formula | CH4O |
| Molecular Weight | 32.0419 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H11N3O3S |
| Molecular Weight | 229.256 |
| Charge | 0 |
| Count |
MOL RATIO
5 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lamivudine is a reverse transcriptase inhibitor used alone or in combination with other classes of anti-human immunodeficiency virus (HIV) drugs in the treatment of HIV infection. This molecule has two stereo-centers, thus giving rise to four stereoisomers: (+/-)-cis-lamivudine and (+/-)-trans-lamivudine. The latter is considered to be impurity of the pharmaceutically active isomer, (-)-cis-lamivudine.
CNS Activity
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
Drug as victim
Sourcing
PubMed
Patents
Sample Use Guides
Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily.
Route of Administration:
Oral
The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines including monocytes and fresh human peripheral blood lymphocytes (PBMCs) using standard susceptibility assays. EC50 values were in the range of 0.003 to 15 microM (1 microM = 0.23 mcg per mL).
